Shunzhong Bao, MD
Endocrinology, Diabetes & Metabolism · Little Rock, ARNPI 1619133519
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $27,965 of the $39,631 with a category attached, or 70.6%. It is spread thinly across 45 manufacturers, the largest accounting for just 19.9%. 2025 is the largest year on record at $13,426, 2.9 times the $4,644 reported in 2019.
Across 860 payments — averaging $46.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cequr Corporation$8K
- Medtronic$7K
- Novo Nordisk$2K
- AstraZeneca$2K
- Zealand Pharma US, Inc.$2K
- Lilly USA, LLC$2K
- plus $18K from 39 others
What the payments were for
- Speaking & faculty fees$8,55022%
- Travel & lodging$2,6897%
- Food & beverage$27,96571%
- Education$3671%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$7,871
- V-GO$2,043
- MINIMED 780G$1,804
- t-slim insulin pump$765
- iLet Bionic Pancreas$745
- INPEN SMART INSULIN DELIVERY SYSTEM$526
- Wegovy$486
- EVENITY$450
- TWIIST$348
- Vascepa$344
- Minimed 670G System$302
- V-GO DISPOSABLE INSULIN DELIVERY$300
- MINIMED 770G$274
- CRYSVITA$269
- AFREZZA$254
- iLet Insulin Infusion Kit Inset$248
- iLet Insulin Infusion Kit Contact Detach$248
- JARDIANCE$240
- Strensiq$238
- Ozempic$228
How this compares
$39,631 in reported general payments places this provider in the 80th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,258 | $1,449,777 |
| JardianceEmpagliflozin | 699 | $584,916 |
| TrulicityDulaglutide | 326 | $374,050 |
| MounjaroTirzepatide | 250 | $268,907 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 196 | $198,858 |
| KerendiaFinerenone | 223 | $165,629 |
| FarxigaDapagliflozin Propanediol | 180 | $145,742 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 148 | $134,914 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 117 | $83,582 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 95 | $78,303 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 194 | $76,040 |
| Tresiba Flextouch U-100Insulin Degludec | 133 | $73,480 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $63,908 |
| JanuviaSitagliptin Phosphate | 95 | $55,613 |
| LyumjevInsulin Lispro-Aabc | 47 | $48,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $2,053 | $1,494,0801,359 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev, Humalog | $1,506 | $711,668699 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $1,151 | $617,728761 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $811 | $198,858196 claims |
| BayerKerendia | $869 | $165,629223 claims |
| AstraZenecaFarxiga | $1,675 | $145,742180 claims |
| MerckJanuvia, Janumet | $51 | $70,189118 claims |
| Cequr CorporationCequr Simplicity | $7,871 | $23,64930 claims |
| AbbVieSynthroid | $680 | $15,293237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in Little Rock
- Richard GriffithsLittle Rock$925K
- James ThrasherLittle Rock$349K
- Richard RappLittle Rock$47K
- Teresa NimmoLittle Rock$29K
- Madhu BudhrajaLittle Rock$29K
- Joseph HenskeLittle Rock$23K
- Nidhi JainLittle Rock$9K
- Archana JarathiLittle Rock$7K
- Allen ReddingLittle Rock$7K
- Zulekha HamidLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.